Kynurenine pathway can be a potential biomarker of fatigue in primary Sjögren's syndrome

被引:0
|
作者
Park, Y. [1 ]
Lee, J. J. [1 ]
Koh, J. H. [2 ]
Kim, M. -j. [3 ,4 ]
Park, S. -h. [3 ]
Kwok, S. -k. [3 ,5 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Rheumatol, Seoul, South Korea
[2] Catholic Univ Korea, Uijeongbu St Marys Hosp, Coll Med, Dept Internal Med,Div Rheumatol, Uijeongbu Si, South Korea
[3] Catholic Univ Korea, Catholic Res Inst Med Sci, Coll Med, Rheumatism Res Ctr, Seoul, South Korea
[4] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, Seoul, South Korea
[5] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Rheumatol, 222 Banpo Daero, Seoul 06591, South Korea
关键词
Sjogren's syndrome; fatigue; biomarkers; tryptophan; kynurenine; PRIMARY SJOGRENS-SYNDROME; SIGNATURES; CONSENSUS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Primary Sjogren's syndrome (pSS) is a chronic autoimmune disease with low quality of life caused by various constitutional symptoms and glandular dysfunction. Although fatigue is one of the most frequent symptoms in pSS, its aetiology or biomarkers are poorly elucidated. We investigated potential relationship between severity of fatigue and the kynurenine pathway in pSS. Methods Clinical data and blood samples of 81 patients were obtained from a prospective cohort for pSS and compared with age-and sex-matched healthy controls (HC). Severity of fatigue was defined according to the fatigue domain scores in the ESSPRI. Potential biomarkers related to the kynurenine pathway were determined using ELISA. Results Of the total, 44 patients were defined as the "severe fatigue (ESSPRI fatigue >= 5)" group, whereas 37 as the "less fatigue (ESSPRI fatigue <5)". Serum tryptophan levels in the severe fatigue group were significantly lower while those of kynurenine were higher than in the others. Serum interferon gamma, IDO1, and quinolinic acid levels were mostly higher in the less fatigue group. Kynurenine/tryptophan ratios were distinctly higher in the severe fatigue group than both HC and the less fatigue group (p<0.001). This ratio showed a strong degree of positive correlation (r=0.624, p <0.001) with severity of fatigue in pSS while the other markers showed fair degrees of correlation.Conclusion Serum markers related to the kynurenine pathway, especially the kynurenine/tryptophan ratio, may be associated with severity of fatigue in pSS. These results can provide guidance for further investigations on fatigue in pSS.
引用
收藏
页码:2363 / 2370
页数:8
相关论文
共 50 条
  • [21] Exploring the biological basis of fatigue using primary Sjögren's syndrome as a disease model
    Andini Savietri Natasari
    Jessica Tarn
    Roman Fischer
    Dennis Lendrem
    Wan Fai Ng
    BMC Musculoskeletal Disorders, 14 (Suppl 1)
  • [22] The Effects of Noninvasive Vagus Nerve Stimulation on Fatigue in Participants With Primary Sj?gren?s Syndrome
    Tarn, Jessica
    Evans, Evelyn
    Traianos, Emmanuella
    Collins, Alexis
    Stylianou, Mryto
    Parikh, Jehill
    Bai, Yang
    Guan, Yu
    Frith, James
    Lendrem, Dennis
    Macrae, Victoria
    McKinnon, Iain
    Simon, Bruce S.
    Blake, Justyna
    Baker, Mark R.
    Taylor, John Paul
    Watson, Stuart
    Gallagher, Peter
    Blamire, Andrew
    Newton, Julia
    Ng, Wan-Fai
    NEUROMODULATION, 2023, 26 (03): : 681 - 689
  • [23] Depression is the most significant independent predictor of fatigue in patients with primary Sjögren's syndrome
    Ayar, Koray
    Aksoy, Meliha Kasapoglu
    Hattatoglu, Tulay Dilara
    Yesil, Busra
    ARCHIVES OF RHEUMATOLOGY, 2023, 38 (03) : 375 - 386
  • [24] Sjögren’s syndrome
    Geza Balint
    W. Watson Buchanan
    Colin A. Kean
    Walter Kean
    K. D. Rainsford
    Inflammopharmacology, 2024, 32 : 37 - 43
  • [25] CXCL9 may serve as a potential biomarker for primary Sjögren's syndrome with extra-glandular manifestations
    Hong, Jingwei
    Cheng, Hui
    Wang, Ping
    Wu, Yanzhi
    Lu, Saisai
    Zhou, Yan
    Wang, Xiao Bing
    Zhu, Xiaofang
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [26] Treatment of primary Sjögren syndrome
    Alain Saraux
    Jacques-Olivier Pers
    Valérie Devauchelle-Pensec
    Nature Reviews Rheumatology, 2016, 12 : 456 - 471
  • [27] Anti-parietal cell antibodies as a potential biomarker for interstitial lung disease associated with primary Sjögren's syndrome
    Zhang, Na
    Wang, Hui
    Sun, Wenwen
    Hou, Hou
    Du, Jun
    Xu, Jiaojiao
    Wei, Wei
    MEDICINA CLINICA, 2024, 162 (01): : 1 - 8
  • [28] CXCL9 may serve as a potential biomarker for primary Sjögren’s syndrome with extra-glandular manifestations
    Jingwei Hong
    Hui Cheng
    Ping Wang
    Yanzhi Wu
    Saisai Lu
    Yan Zhou
    Xiao bing Wang
    Xiaofang Zhu
    Arthritis Research & Therapy, 26
  • [29] Comment on: Can Raynaud’s phenomenon be defined as a subtype of primary Sjögren’s syndrome? Comments on “Clinical features and risk factors of Raynaud’s phenomenon in primary Sjögren’s syndrome” Reply
    Lin Wei
    Yang Liu
    Zhang Fengxiao
    Clinical Rheumatology, 2022, 41 : 1267 - 1268
  • [30] New biomarker for Sjögren's syndrome—time to treat patients
    Frans G. M. Kroese
    Hendrika Bootsma
    Nature Reviews Rheumatology, 2013, 9 : 570 - 572